News & Updates

For pregnant women with HIV who are receiving dolutegravir (DTG)-based therapies, the two-drug regimen works just as well as three-drug regimens at keeping the viral load to "undetectable" levels without exerting serious adverse effects on neonatal outcomes, according to a study presented at HIV Glasgow 2022 Congress.

Adult people with HIV-1 (PLHIV) who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after initially taking dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) or DTG+F/TAF show a consistently high virologic suppression and have few discontinuations over 5 years of follow-up, according to a study presented at the HIV Glasgow 2022 Congress.

Patients who are on long-term statin therapy may have a reduced risk of severe COVID-19–related outcomes including mortality, intensive care unit (ICU) admission, and requirement for mechanical ventilation, according to a study presented at Anesthesiology 2022.

A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.

Coinfection of tuberculosis (TB) among people with HIV initiating antiretroviral therapy (ART) aggravates the risk of death, a recent study has found.

Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.